Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 4,493,794 shares, a decrease of 2.8% from the October 13th total of 4,621,391 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 901,427 shares, the days-to-cover ratio is currently 5.0 days.

Separately, ValuEngine upgraded Navidea Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st.

A number of institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC grew its holdings in Navidea Biopharmaceuticals by 7.2% during the first quarter. HighTower Advisors LLC now owns 177,966 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 11,900 shares in the last quarter. Vanguard Group Inc. grew its holdings in Navidea Biopharmaceuticals by 1.7% during the second quarter. Vanguard Group Inc. now owns 4,887,743 shares of the biopharmaceutical company’s stock worth $2,492,000 after buying an additional 80,499 shares in the last quarter. Finally, Virtu KCG Holdings LLC grew its holdings in Navidea Biopharmaceuticals by 305.6% during the second quarter. Virtu KCG Holdings LLC now owns 336,414 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 253,471 shares in the last quarter.

Shares of Navidea Biopharmaceuticals (NYSEMKT NAVB) traded up $0.01 during trading on Monday, reaching $0.42. The company had a trading volume of 148,494 shares, compared to its average volume of 485,648. Navidea Biopharmaceuticals has a 1-year low of $0.29 and a 1-year high of $1.16.

Navidea Biopharmaceuticals (NYSEMKT:NAVB) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 65.90% and a negative net margin of 515.33%. The company had revenue of $0.22 million for the quarter.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/13/navidea-biopharmaceuticals-inc-navb-short-interest-update.html.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Receive News & Ratings for Navidea Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.